FinTrust Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

FinTrust Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$65.1K	Hold	140	–	–	0.01%	510
2024 Q2	$65.6K	Buy	140 +16	+13%	+$6.95K	0.01%	477
2024 Q1	$51.8K	Hold	124	–	–	0.01%	510
2023 Q4	$50.5K	Buy	124 +10	+9%	+$3.69K	0.01%	487
2023 Q3	$39.6K	Sell	114 -160	-58%	-$56K	0.01%	504
2023 Q2	$79.1K	Hold	274	–	–	0.02%	382
2023 Q1	$79.1K	Hold	274	–	–	0.02%	380
2022 Q4	$79.1K	Sell	274 -1,000	-78%	-$305K	0.02%	380
2022 Q3	$371K	Buy	+1,274	New	+$367K	0.1%	187
2021 Q3	–	Sell	-50	Closed	-$10K	–	1221
2021 Q2	$10K	Sell	50 -9	-15%	-$1.88K	﹤0.01%	945
2021 Q1	$13K	Hold	59	–	–	﹤0.01%	839
2020 Q4	$14K	Sell	59 -264	-82%	-$60.6K	﹤0.01%	763
2020 Q3	$88K	Buy	323 +10	+3%	+$2.76K	0.02%	384
2020 Q2	$91K	Sell	313 -24	-7%	-$6.51K	0.04%	356
2020 Q1	$80K	Buy	337 +16	+5%	+$3.67K	0.04%	328
2019 Q4	$70K	Sell	321 -27	-8%	-$5.46K	0.03%	384
2019 Q3	$59K	Hold	348	–	–	0.02%	416
2019 Q2	$63K	Sell	348 -24	-6%	-$4.2K	0.03%	371
2019 Q1	$68K	Sell	372 -30	-7%	-$5.54K	0.03%	339
2018 Q4	$67K	Buy	+402	New	+$69.7K	0.03%	326

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

FinTrust Capital Advisors's VRTX Position: Q3 2024 in Review

FinTrust Capital Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2024 at 140 shares worth $65.1K. The position accounts for 0.01% of the portfolio, ranked #510.

FinTrust Capital Advisors first reported a position in VRTX in Q4 2018 and has held it in 20 quarters since. The position peaked at $371K in Q3 2022. 1,547 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

FinTrust Capital Advisors held 140 shares of Vertex Pharmaceuticals worth $65.1K as of Q3 2024.
FinTrust Capital Advisors left its Vertex Pharmaceuticals share count unchanged in Q3 2024.
Vertex Pharmaceuticals made up 0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #510 holding.
FinTrust Capital Advisors first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 20 quarters since.
FinTrust Capital Advisors's Vertex Pharmaceuticals position peaked at $371K in Q3 2022.
1,547 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.